BARR CLEARED TO LAUNCH ADDERALL IR

Barr Pharmaceuticals, Inc. announced that the Hart-Scott-Rodino ("HSR") waiting period for the company's acquisition of Shire plc's ADDERALL (immediate-release mixed amphetamine salts) product has expired without further action from the U.S. Federal Trade Commission ("FTC"). As a result, the product acquisition agreement that Duramed Pharmaceuticals, Inc., a subsidiary of Barr, and Shire entered into on August 14, 2006, can be finalized. Under the terms of the agreement, Duramed will pay $63 million to purchase Shire's ADDERALL (immediate-release mixed amphetamine salts) tablets. The company will launch the ADDERALL product in the quarter ending December 31, 2006.

Yahoo Finance (http://biz.yahoo.com/prnews/060928/nyth025.html?.v=66)